Lipid CME

This activity is expired and is no longer available for CME credit.


Utilizing PCSK9 Inhibitors: Who? When? How Long?

Author(s)/Faculty: Robert P. Giugliano, MD, SM, FACC, FAHA; Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA
Release Date: 11/21/2016Expiration Date: 11/20/2017
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Elevated LDL-C levels contribute to enhanced cardiovascular risk. Despite reducing the risk of cardiovascular disease, residual risk remains in patients taking statins. This CME activity will discuss the use of PCSK9 inhibitors in patients with elevated LDL-C levels who are at risk for cardiovascular disease, despite statin therapy.